DelveInsight’s “Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hyperphosphatemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Hyperphosphatemia drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hyperphosphatemia treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hyperphosphatemia: An Overview
Hyperphosphatemia is a condition characterized by an increase in serum phosphate levels above 4.5 mg/100 mL. The condition usually occurs due to a decrement in renal function, commonly among chronic kidney disease (CKD) patients, in which phosphate levels shoot up abnormally high.
Hyperphosphatemia does not usually have apparent symptoms. It is more likely that the symptoms of an underlying disease that can cause high phosphate levels, such as uncontrolled diabetes, are spotted first. More commonly, patients report uremic symptoms such as fatigue, shortness of breath, anorexia, nausea, vomiting, and sleep disturbances. If phosphate levels in the blood become too high, it may cause mineral and bone disorders and calcification. Also, hyperphosphatemia complexes serum calcium, decreasing the levels of ionized calcium and triggering PTH release, resulting in secondary hyperparathyroidism; this causes a high bone turnover state, releasing calcium from the bone to normalize the serum calcium level.
Kidney disease is the most common cause of hyperphosphatemia. Other conditions linked with high levels of phosphate in the blood include uncontrolled diabetes, diabetic ketoacidosis, hypoparathyroidism, high intake of phosphate, vitamin D intoxication, genetic deficiencies, and consumption of phosphate supplements.
Treatment for the condition includes restriction of phosphate intake and administration of phosphate-binding antacids, such as calcium carbonate, which can help normalize the phosphate levels in the blood. Dietary modification or consuming a low-phosphorus diet is also necessary, especially in the case of kidney patients. FDA-approved phosphate binder therapies for the treatment of the condition include Kiklin, Auryxia/ Riona/ Nephoxil, and Velphoro/ P-TOL.
The treatment landscape of hyperphosphatemia in the US is typically divided into first- and second-line treatment. Sevelamer-based phosphate binders (Renvela/Renagel), calcium-based binders (Phoslo and Phoslyra), a combination of sevelamer and calcium phosphate binders, and iron-based phosphate binders (Velphoro and Auryxia) are given as the first-line therapy to the patients with hyperphosphatemia, followed by monotherapy or combination of these phosphate binders as the second-line therapy.
Hyperphosphatemia Market Key Facts
-
In 2021, in the United States, the prevalence of ESRD was 803,301, and patients with ESRD on dialysis accounted for 570,344 cases.
-
In the United States, the patients with Stage 3–5 CKD accounted for 2,359,056 in 2021.
-
The United States, in 2021, accounted for 484,792 prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis. Among EU5 countries, Germany had the highest number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which was 55,742 in 2021. Whereas, Spain accounted for the least number of prevalent cases of hyperphosphatemia in ESRD patients undergoing dialysis, which were 23,981.
-
Rastogi et al. (2021) provided strategies to control hyperphosphatemia based on a systematic literature review of clinical trials and real-world observational data on phosphorus control in hemodialysis patients with CKD-mineral bone disorder (CKD-MBD). The study stated that although less than 5% of people with normal kidney function or those in CKD stages 1 and 2 exhibit hyperphosphatemia, the prevalence increases in CKD stage 3b and becomes incrementally higher in stages 4 (∼20%) and 5 (∼40%). By the time a patient receives dialysis, they are highly likely to be hyperphosphatemic.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hyperphosphatemia pipeline therapies. It also thoroughly assesses the Hyperphosphatemia market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Hyperphosphatemia drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hyperphosphatemia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Hyperphosphatemia epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Hyperphosphatemia epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Hyperphosphatemia Epidemiology, Segmented as –
-
Prevalent Cases of End-Stage Renal Disease (ESRD) in 7MM [2019–2032]
-
Prevalence of Hyperphosphatemia in 7MM [2019–2032]
-
Total Prevalent Cases of Chronic Kidney Disease (CKD) in 7MM [2019–2032]
-
Diagnosed Prevalent Cases of Chronic Kidney (CKD) in 7MM [2019–2032]
-
Stage-specific Distribution of Chronic Kidney (CKD) in 7MM [2019–2032]
-
Number of ESRD patients undergoing Dialysis in 7MM [2019–2032]
Hyperphosphatemia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hyperphosphatemia market or expected to be launched during the study period. The analysis covers the Hyperphosphatemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Hyperphosphatemia drugs based on their sale and market share.
The report also covers the Hyperphosphatemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Hyperphosphatemia companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Hyperphosphatemia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/hyperphosphatemia-market
Hyperphosphatemia Therapeutics Analysis
Treatment for hyperphosphatemia depends on the underlying condition. For people with kidney disease, a combination of diet and medication is used to keep phosphate levels under control. In patients with good renal function, renal phosphate excretion can be increased through extracellular volume expansion by saline infusion and diuretics. If renal function is impaired, it is an indication for hemodialysis.
Several treatment strategies that can be employed to tackle hyperphosphatemia include dietary restriction, phosphate binders (aluminum-based agents, calcium-based binders, magnesium carbonate, sevelamer, lanthanum carbonate, ferric citrate and sucroferric oxyhydroxide), drugs targeting intestinal phosphate transporters (tenapanor, nicotinic acid and nicotinamide), renal replacement therapies (peritoneal and hemodialysis) and management of secondary hyperparathyroidism.
Several major pharma and biotech companies are developing therapies for Hyperphosphatemia. Currently, PUMC Pharmaceutical is leading the therapeutics market with its Hyperphosphatemia drug candidates in the most advanced stage of clinical development.
Expected launch of potential therapies like Tenapanor and PT20 by the key players Ardelyx and Shield Therapeutics, respectively, may increase market size in the coming years, assisted by an increase in the prevalent population of Hyperphosphatemia.
Hyperphosphatemia Companies Actively Working in the Therapeutics Market Include
PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and many others.
Emerging and Marketed Hyperphosphatemia Therapies Covered in the Report Include:
-
FC818 (ferric citrate): PUMC Pharmaceutical
-
VS 505: Shanghai Alebund Pharmaceuticals
-
Auryxia/Nephoxil/Riona: Akebia Therapeutics
-
Velphoro/ P-TOL: Vifor Fresenius Medical Care Renal Pharma
-
Kiklin: Astellas Pharma
-
Ibsrela (tenapanor): Ardelyx
-
PT20: Shield Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/hyperphosphatemia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hyperphosphatemia Competitive Intelligence Analysis
4. Hyperphosphatemia Market Overview at a Glance
5. Hyperphosphatemia Disease Background and Overview
6. Hyperphosphatemia Patient Journey
7. Hyperphosphatemia Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Hyperphosphatemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Hyperphosphatemia Unmet Needs
10. Key Endpoints of Hyperphosphatemia Treatment
11. Hyperphosphatemia Marketed Therapies
12. Hyperphosphatemia Emerging Drugs and Latest Therapeutic Advances
13. Hyperphosphatemia Seven Major Market Analysis
14. Attribute Analysis
15. Hyperphosphatemia Market Outlook (In US, EU5, and Japan)
16. Hyperphosphatemia Companies Active in the Market
17. Hyperphosphatemia Access and Reimbursement Overview
18. KOL Views on the Hyperphosphatemia Market
19. Hyperphosphatemia Market Drivers
20. Hyperphosphatemia Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/hyperphosphatemia-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Gestational Diabetes Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Gestational Diabetes market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Gestational Diabetes market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices